Shattuck Labs (NASDAQ:STTK) Announces Earnings Results

Posted by Lindsey Winhoffer on May 4th, 2024

Shattuck Labs (NASDAQ:STTK – Get Free Report) released its earnings results on Thursday. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08, Briefing.com reports. The firm had revenue of $1.15 million during the quarter, compared to analyst estimates of $0.30 million. Shattuck Labs had a negative net margin of 3,133.63% and a negative return on equity of 64.46%. The company’s quarterly revenue was up 2200.0% on a year-over-year basis.

Shattuck Labs Trading Down 2.9 %

NASDAQ STTK traded down $0.32 on Friday, reaching $10.78. The company’s stock had a trading volume of 255,663 shares, compared to its average volume of 294,183. The firm has a market cap of $512.59 million, a PE ratio of -5.59 and a beta of 1.98. The business has a 50-day moving average price of $9.42 and a 200 day moving average price of $6.95. Shattuck Labs has a 52 week low of $1.33 and a 52 week high of $11.62.

Insider Activity at Shattuck Labs

In related news, insider Stephen Stout sold 16,004 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $10.53, for a total value of $168,522.12. Following the sale, the insider now owns 74,437 shares of the company’s stock, valued at $783,821.61. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 9.89% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price objective on shares of Shattuck Labs in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Shattuck Labs in a research report on Thursday.

Read Our Latest Report on Shattuck Labs

Shattuck Labs Company Profile

(Get Free Report)

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.